Clinical Trials Directory

Trials / Conditions / Blood Protein Disorders

Blood Protein Disorders

11 registered clinical trials studyying Blood Protein Disorders — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185
Kelonia Therapeutics, Inc.Phase 1
RecruitingA Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT06271252
OriCell Therapeutics Co., Ltd.Phase 1
RecruitingA Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide,
NCT05573802
Hellenic Society of HematologyPhase 1 / Phase 2
Not Yet RecruitingA Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumuma
NCT05581875
Hellenic Society of HematologyPhase 1 / Phase 2
UnknownA Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received O
NCT05298683
Hellenic Society of HematologyPhase 2
UnknownA Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumuma
NCT05280275
Hellenic Society of HematologyPhase 1 / Phase 2
UnknownA Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by I
NCT05147493
Hellenic Society of HematologyPhase 2
UnknownNatural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
NCT04309084
Celularity IncorporatedPhase 1
UnknownBedside Assessment of Coagulation in Post-partum Hemorrhage by Thromboelastography (TEG ®6S)
NCT03592303
Assistance Publique - Hôpitaux de Paris—
WithdrawnContinuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or T
NCT02155634
CelgenePhase 3
CompletedTransfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients
NCT00751322
Mayo ClinicN/A